サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467746

次世代糖尿病治療とドラッグデリバリー市場：製品タイプ、人口動態、適応症、エンドユーザー、地域別、2024～2032年

Next Generation Diabetes Therapy and Drug Delivery Market by Product Type, Demographic (Adult Population, Child Population ), Indication, End User (Diagnostic/Clinics, Intensive Care Units, Home Healthcare), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
次世代糖尿病治療とドラッグデリバリー市場：製品タイプ、人口動態、適応症、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

次世代糖尿病治療とドラッグデリバリーの世界市場規模は、2023年に98億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて14.23%の成長率（CAGR）を示し、2032年までに335億米ドルに達すると予測しています。糖尿病、特に2型糖尿病の有病率の上昇、継続的な技術の進歩、高齢者人口の増加が市場を牽引する主要要因のいくつかです。

次世代糖尿病治療とドラッグデリバリーは、インスリンを患者の体内に低侵襲で導入することに重点を置き、注射針を頻繁に使用することによる皮膚刺激のリスクを軽減します。この患者に優しいアプローチは、ウェアラブルセンサー、マイクロニードル、吸入インスリンなどの革新的な技術を活用することで、医療コストを削減しながら効果的に病気を管理することを目的としています。持続グルコースモニタリングシステム（CGMS）、人工膵臓、インスリンパッチなどの先進治療も、糖尿病関連合併症のリスクを最小限に抑える血糖値管理を改善するために採用されています。また、投与量の計算が容易で、リアルタイムで血糖値をチェックでき、痛みもなくインスリンを体内に投与できるため、投与時間の維持にも役立っています。この治療法とドラッグデリバリーの利点には、患者の転帰の改善、治療効率の向上、患者の糖尿病管理負担の最小化などがあり、より的を絞った治療計画につながります。

次世代糖尿病治療とドラッグデリバリーの市場動向：

世界市場は主に、大衆の間で糖尿病、特に2型糖尿病の有病率が上昇していることが原動力となっています。この背景には、不健康な食生活の増加、座りがちなライフスタイル、身体活動の低下があります。これに伴い、個人のニーズ、ライフスタイル、治療目標に応じて個別化された患者中心のケアに対する需要が高まっており、その結果、製品の普及が進んでいます。さらに、スマートインスリンペン、クローズドループシステム、副作用の少ない埋め込み型デバイスの開発など、継続的な技術進歩が市場に刺激を与えています。これに加えて、個人の間で低侵襲で痛みの少ない治療オプションが重視されるようになっていることも、市場の重要な成長促進要因として作用しています。さらに、医療費の増加や、価値別の医療ソリューションへの注目の高まりも市場を牽引しています。しかし、新興国市場では、コスト抑制の高まり、認知度の不足、製品のばらつきの少なさが、市場の主要な成長抑制要因として作用しています。逆に、予防医療や早期介入に関する政府の好意的な取り組みや償還政策の実施は、市場に明るい展望をもたらしています。これとは別に、慢性疾患を発症しやすい高齢者人口の増加が市場に好影響を与えています。市場に寄与するその他の要因としては、急速な都市化、従来の糖尿病治療に伴う合併症に対する意識の高まり、遠隔医療やデジタルヘルスソリューションの採用増加、可処分所得水準の上昇、主要企業による広範な研究開発（R&D）活動などが挙げられます。

本レポートで扱う主要質問

  • 世界の次世代糖尿病治療とドラッグデリバリー市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界の次世代糖尿病治療とドラッグデリバリー市場における促進要因、抑制要因、機会は何か？
  • それぞれの促進要因、抑制要因、機会が世界の次世代糖尿病治療とドラッグデリバリー市場に与える影響は？
  • 主要な地域市場とは？
  • 次世代糖尿病治療とドラッグデリバリーの世界市場で最も魅力的な国は？
  • 製品タイプ別の市場内訳は？
  • 次世代糖尿病治療とドラッグデリバリーの世界市場で最も魅力的な製品タイプは？
  • 人口動態別の市場内訳は？
  • 次世代糖尿病治療とドラッグデリバリーの世界市場で最も魅力的な人口動態は？
  • 適応症別の市場内訳は？
  • 次世代糖尿病治療とドラッグデリバリーの世界市場で最も魅力的な適応症は？
  • エンドユーザー別の市場内訳は？
  • 次世代糖尿病治療とドラッグデリバリーの世界市場で最も魅力的なエンドユーザーは？
  • 世界の次世代糖尿病治療とドラッグデリバリー市場の競合構造は？
  • 次世代糖尿病治療とドラッグデリバリーの世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 次世代糖尿病治療とドラッグデリバリーの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • 吸入インスリン製剤
  • 経口インスリン
  • インスリンパッチ
  • CGMシステム
  • 人工膵臓

第7章 市場内訳：人口動態別

  • 成人人口（14歳以上）
  • 幼児人口（14歳以下）

第8章 市場内訳：適応症別

  • 1型糖尿病
  • 2型糖尿病

第9章 市場内訳：エンドユーザー別

  • 診断/クリニック
  • 集中治療室（ICU）
  • 在宅医療

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Dexcom Inc.
    • Eli Lilly and Company
    • Enteris BioPharma Inc.（Swk Holdings Corporation）
    • GlySens Incorporated
    • MannKind Corporation
    • Medtronic plc
    • Sanofi
    • Senseonics
図表

List of Figures

  • Figure 1: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Breakup by Demographic (in %), 2023
  • Figure 6: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Next Generation Diabetes Therapy and Drug Delivery (Inhalable Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Next Generation Diabetes Therapy and Drug Delivery (Inhalable Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Next Generation Diabetes Therapy and Drug Delivery (Oral Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Next Generation Diabetes Therapy and Drug Delivery (Oral Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Next Generation Diabetes Therapy and Drug Delivery (Insulin Patches) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Next Generation Diabetes Therapy and Drug Delivery (Insulin Patches) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Next Generation Diabetes Therapy and Drug Delivery (CGM Systems) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Next Generation Diabetes Therapy and Drug Delivery (CGM Systems) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Next Generation Diabetes Therapy and Drug Delivery (Artificial Pancreas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Next Generation Diabetes Therapy and Drug Delivery (Artificial Pancreas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Next Generation Diabetes Therapy and Drug Delivery (Adult Population (>14 Years)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Next Generation Diabetes Therapy and Drug Delivery (Adult Population (>14 Years)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Next Generation Diabetes Therapy and Drug Delivery (Child Population (14 Years)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Next Generation Diabetes Therapy and Drug Delivery (Child Population (14 Years)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Next Generation Diabetes Therapy and Drug Delivery (Type 1 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Next Generation Diabetes Therapy and Drug Delivery (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Next Generation Diabetes Therapy and Drug Delivery (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Next Generation Diabetes Therapy and Drug Delivery (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Next Generation Diabetes Therapy and Drug Delivery (Diagnostic/Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Next Generation Diabetes Therapy and Drug Delivery (Diagnostic/Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Next Generation Diabetes Therapy and Drug Delivery (Intensive Care Units (ICUs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Next Generation Diabetes Therapy and Drug Delivery (Intensive Care Units (ICUs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Next Generation Diabetes Therapy and Drug Delivery (Home Healthcare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Next Generation Diabetes Therapy and Drug Delivery (Home Healthcare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: North America: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: North America: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: United States: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: United States: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Canada: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Canada: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Asia-Pacific: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Asia-Pacific: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: China: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: China: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Japan: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Japan: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: India: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: India: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: South Korea: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: South Korea: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Australia: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Australia: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Indonesia: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Indonesia: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Others: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Others: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Europe: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Europe: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Germany: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Germany: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: France: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: France: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: United Kingdom: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: United Kingdom: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Italy: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Italy: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Spain: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Spain: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Russia: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Russia: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Latin America: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Latin America: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Brazil: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Brazil: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Mexico: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Mexico: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Middle East and Africa: Next Generation Diabetes Therapy and Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Middle East and Africa: Next Generation Diabetes Therapy and Drug Delivery Market: Breakup by Country (in %), 2023
  • Figure 81: Middle East and Africa: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Global: Next Generation Diabetes Therapy and Drug Delivery Industry: Drivers, Restraints, and Opportunities
  • Figure 83: Global: Next Generation Diabetes Therapy and Drug Delivery Industry: Value Chain Analysis
  • Figure 84: Global: Next Generation Diabetes Therapy and Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Breakup by Demographic (in Million US$), 2024-2032
  • Table 4: Global: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Next Generation Diabetes Therapy and Drug Delivery Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Competitive Structure
  • Table 8: Global: Next Generation Diabetes Therapy and Drug Delivery Market: Key Players
目次
Product Code: SR112024A7519

The global next generation diabetes therapy and drug delivery market size reached US$ 9.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 33.5 Billion by 2032, exhibiting a growth rate (CAGR) of 14.23% during 2024-2032. The rising prevalence of diabetes, particularly type-2 diabetes, continual technological advancements, and the growing geriatric population represent some of the key factors driving the market.

Next generation diabetes therapy and drug delivery procedure focuses on the introduction of insulin into the patient's body in a minimally invasive manner to reduce the risk of skin irritation from frequent needle usage. This patient-friendly approach aims to effectively manage the disease while reducing healthcare costs by utilizing innovative technologies including wearable sensors, micro-needles, and inhalable insulin. Advanced therapies, such as continuous glucose monitoring systems (CGMS), artificial pancreas, and insulin patches, are also employed to improve blood sugar level management that minimize the risks of diabetic-related complications. In addition, the procedure facilitates easy calculation of the dose volume, checking the blood glucose levels in real-time, and delivers insulin into the body painlessly, which, in turn, helps to maintain the dosage time. Some of the advantages of this therapy and drug delivery practice includes improved patient outcomes, enhanced treatment efficiency, and minimized burden of diabetes management for patients, leading to more targeted treatment plans.

Next Generation Diabetes Therapy and Drug Delivery Market Trends:

The global market is primarily driven by the rising prevalence of diabetes, particularly type-2 diabetes, among the masses. This can be attributed to the increasing consumption of unhealthy diets, sedentary lifestyles and reduced physical activity. In line with this, the augmenting demand for personalized and patient-centric care according to individual needs, lifestyle, and treatment goals is resulting in a higher product uptake. Moreover, continual technological advancements, such as the development of smart insulin pens, closed-loop systems, and implantable devices with fewer side effects, is providing an impetus to the market. In addition to this, the increasing emphasis on minimally invasive and pain-free treatment options among individuals is also acting as a significant growth-inducing factor for the market. The market is further driven by the increasing healthcare expenditure, along with an enhanced focus on value-based medical care solutions. However, the growing cost restrains, lack of awareness and less variability in products in the developing regions are acting as major growth-restraining factors for the market. Conversely, the implementation of favorable government initiatives and reimbursement policies regarding preventive healthcare and early intervention is creating a positive outlook for the market. Apart from this, the growing geriatric population that is more susceptible to developing chronic diseases is impacting the market favorably. Some of the other factors contributing to the market include rapid urbanization, increasing awareness regarding the associated complications of traditional diabetes treatment, rising adoption of telehealth and digital health solutions, inflating disposable income levels and extensive research and development (R&D) activities conducted by key players.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global next generation diabetes therapy and drug delivery market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, demographic, indication, and end user.

Product Type Insights:

Inhalable Insulin

Oral Insulin

Insulin Patches

CGM Systems

Artificial Pancreas

The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the product type. This includes inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. According to the report, CGM systems represented the largest segment.

Demographic Insights:

Adult Population (>14 Years)

Child Population (14 Years)

The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the demographic. This includes adult population (>14 years) and child population (14 years). According to the report, adult population (>14 years) represented the largest segment.

Indication Insights:

Type 1 diabetes

Type 2 diabetes

The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the indication. This includes type 1 diabetes, type 2 diabetes. According to the report, type 2 diabetes represented the largest segment.

End User Insights:

Diagnostic/Clinics

Intensive Care Units (ICUs)

Home Healthcare

A detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the end user has also been provided in the report. This includes diagnostic/clinics, intensive care units (ICUs), and home healthcare. According to the report, diagnostic/clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for next generation diabetes therapy and drug delivery. Some of the factors driving the North America next generation diabetes therapy and drug delivery market included the aging population, continual technological advancements, high healthcare expenditure, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global next generation diabetes therapy and drug delivery market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Dexcom Inc., Eli Lilly and Company, Enteris BioPharma Inc. (Swk Holdings Corporation), GlySens Incorporated, MannKind Corporation, Medtronic plc, Sanofi, Senseonics, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global next generation diabetes therapy and drug delivery market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global next generation diabetes therapy and drug delivery market?
  • What is the impact of each driver, restraint, and opportunity on the global next generation diabetes therapy and drug delivery market?
  • What are the key regional markets?
  • Which countries represent the most attractive global next generation diabetes therapy and drug delivery market?
  • What is the breakup of the market based on the product type?
  • Which is the most attractive product type in the global next generation diabetes therapy and drug delivery market?
  • What is the breakup of the market based on the demographic?
  • Which is the most attractive demographic in the global next generation diabetes therapy and drug delivery market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the global next generation diabetes therapy and drug delivery market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the global next generation diabetes therapy and drug delivery market?
  • What is the competitive structure of the global next generation diabetes therapy and drug delivery market?
  • Who are the key players/companies in the global next generation diabetes therapy and drug delivery market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Next Generation Diabetes Therapy and Drug Delivery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Inhalable Insulin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Oral Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Insulin Patches
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CGM Systems
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Artificial Pancreas
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Demographic

  • 7.1 Adult Population (>14 Years)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Child Population (14 Years)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Type 1 Diabetes
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type 2 Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Diagnostic/Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Intensive Care Units (ICUs)
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Home Healthcare
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Dexcom Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Eli Lilly and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Enteris BioPharma Inc. (Swk Holdings Corporation)
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 GlySens Incorporated
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 MannKind Corporation
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Medtronic plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Sanofi
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Senseonics
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.